Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carbosylane is a combination gastrointestinal medication containing activated charcoal (140 mg) and simethicone (45 mg). Developed by Laboratoires Grimberg, it is primarily used for the symptomatic relief of intestinal gas, bloating (meteorism), and functional dyspepsia. The formulation is unique, consisting of two twinned capsules: a blue gastric-soluble capsule that releases its contents in the stomach and a red gastro-resistant capsule that releases in the intestine, ensuring action throughout the digestive tract. Activated charcoal acts as a physical adsorbent, binding gases and toxins in the gut, while simethicone acts as a surfactant to break down gas bubbles by reducing their surface tension, facilitating their expulsion. It is widely available as an over-the-counter treatment in several regions, including France and Israel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on activated charcoal + simethicone.